0000000000465908

AUTHOR

G. Van Dooren

showing 4 related works from this author

Real-world evidence from a European cohort study of patients with treatment resistant depression : Baseline patient characteristics

2021

Journal of affective disorders 283, 115-122 (2021). doi:10.1016/j.jad.2020.11.124

AdultMaleDisease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic status; Adult; Cohort Studies; Europe; Female; Humans; Male; Middle Aged; Quality of Life; Depressive Disorder Major; Depressive Disorder Treatment-Resistantmedicine.medical_specialtyHealth-related quality of lifeSocio-economic statusMajor depressive disorderCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineQuality of lifeObservational studyInternal medicinemedicineHumansMedical historyDepression (differential diagnoses)Disease burdenDepressive DisorderDepressive Disorder MajorPatient-reported outcomesDisease burden Health-related quality of life Major depressive disorder Observational study Patient-reported outcomes Socio-economic statusbusiness.industryTreatment-ResistantMajorDisease burdenMiddle Agedmedicine.disease030227 psychiatry3. Good healthEuropePsychiatry and Mental healthClinical PsychologyPresenteeismQuality of LifeMajor depressive disorderFemalebusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort study
researchProduct

P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week …

2015

Simeprevirmedicine.medical_specialtyMultivariate analysisHepatologybusiness.industryRibavirinVirologyGastroenterologyTherapy naiveRegimenchemistry.chemical_compoundHcv genotype 1chemistryPegylated interferonInternal medicinemedicinebusinessmedicine.drugJournal of Hepatology
researchProduct

PTH-137 Safety and efficacy of simeprevir (SMV) plus PEG-IFN/RBV in treatment-naÏve chronic hepatitis c genotype 1 patients eligible for 12 weeks of …

2015

Introduction HPC3014 is a Phase 3, open-label study to assess if response to SMV+Peg-IFN/RBV at Week 2 can allow shortening of treatment to 12 weeks, irrespective of baseline and on-treatment factors. Method Treatment-naive chronic HCV G1-infected patients with no-to-moderate fibrosis (METAVIR F0–F2) were recruited. In patients with HCV-RNA ® Taqman ® lower limit of quantification: 25 IU/mL, lower limit of detection: 15 IU/mL]) at Week 2 and undetectable at Weeks 4 and 8, all treatments were stopped at Week 12 (12-week group). If these criteria were not met, Peg-IFN/RBV was continued to Week 24 (in one case extended to Week 48). Results 123/163 (76%) patients treated were eligible for the 1…

Simeprevirmedicine.medical_specialtybusiness.industryGastroenterologyNeutropeniamedicine.diseaseRashTherapy naiveChronic hepatitisInternal medicineGenotypemedicineIn patientmedicine.symptombusinessViral loadGut
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics: Patient character…

2021

Background: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. Methods: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. Results: Overall, 411 eligible…

Disease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic statusPatient-reported outcomesHealth-related quality of lifeObservational studySocio-economic statusDisease burdenMajor depressive disorderPsiquiatria
researchProduct